Company news

Rezolute, Inc. news in 2024

Rezolute, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

December 4, 2024

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

December 2, 2024

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

November 6, 2024

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

September 18, 2024

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

September 8, 2024

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

August 4, 2024

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

June 26, 2024

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

June 23, 2024

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

June 12, 2024

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

June 12, 2024

Rezolute to Participate in the Jefferies Global Healthcare Conference

May 29, 2024

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

May 20, 2024

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024

Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting

April 22, 2024

Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)

March 5, 2024

Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update

February 12, 2024

Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer

January 23, 2024

Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

January 22, 2024

Decks in 2024